Vaccines & Vaccination

Biography

Michael G. Hanna is the founder of Vaccinogen and the discoverer and developer of OncoVAX® an autologous vaccine designed to provoke a specific immune response against colon cancer cells. His previous accomplishments include Chairman (Emeritus) and Chief Scientific Officer of Intracel Resources, Chief Operating Officer of Organon Teknika/Biotechnology Research Institute and Sr. Vice President of Organon Teknika Corporation. Prior to that (1975-1982) Michael G. Hanna was Director of the National Cancer Institute, Frederick Cancer Research Center. OncoVAX® is an autologous vaccine designed to provoke a specific immune response against colon cancer cells. The product is comprised of irradiated tumor cells obtained from the patient after surgery and it is administered along with the BCG vaccine. Vaccinogen believes OncoVAX® is the first product to show a significant reduction in recurrence of disease in Stage II colon cancer patients in a major, long-term clinical trial. Except for surgery, there is no medically accepted treatment for Stage II colon cancer. Trials using adjuvant chemotherapy have not demonstrated any patient benefit to date. He led the team that achieved FDA regulatory approval of TICE BCG for treatment of carcinoma in situ (CIS) bladder cancer. Worldwide registration was achieved in 1991 and it is standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. He received a doctoral degree in experimental pathology and immunology from the University of Tennessee. He has over 225 publications to his credit, has 11 patents in immunotherapy and has been the recipient of numerous honors, and served on many editorial boardsBiography

Research Interest

Vaccinogen Inc., USA Discoverer - Developer, OncoVAX® Director, Frederick Cancer Research Center (1975-1983)